https://www.managedhealthcareexecutive.com/watch 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/improving-ophthalmic-care-access-and-treatment 2021-08-26 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/increasing-awareness-around-the-genetic-components-of-als 2022-12-19 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/redefining-menopause-care-practical-strategies-and-emerging-innovations-in-vms-treatment 2025-02-12 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/examining-health-equity-among-different-racial-and-ethnic-subpopulations-with-multiple-sclerosis 2021-06-02 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/wet-age-related-macular-degeneration-understanding-disease-impact-and-refining-treatment-approac 2021-07-21 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/payer-perspectives-in-vitiligo-optimizing-patient-outcomes-with-novel-therapeutic-approaches 2023-09-08 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/optimizing-access-and-utilization-of-fertility-benefits 2023-12-19 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/challenges-and-opportunities-in-the-hemophilia-a-space-insights-into-the-patient-perspective 2023-08-23 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/closing-care-gaps-in-diabetes-management-through-advanced-data-integration-with-continuous 2024-03-11 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/atopic-dermatitis 2021-11-23 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/improving-access-to-alternative-therapies-for-treatment-resistant-depression 2024-09-30 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/advancing-care-in-vitiligo-and-atopic-dermatitis-from-pathogenesis-to-targeted-therapies 2026-04-07 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/the-expansion-of-prescription-digital-therapeutics-in-health-care 2023-04-27 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/key-updates-in-the-management-of-patients-with-vitiligo 2025-12-23 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/secondary-progressive-multiple-sclerosis-patient-impact-and-coverage-implications-for-new 2021-06-04 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/addressing-disparities-in-care-in-women-s-reproductive-health 2022-02-21 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/prescription-digital-therapeutics-reimagining-care-in-behavior-driven-conditions 2022-08-17 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/evaluating-the-current-and-future-opportunities-for-hiv-prep 2021-12-21 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/navigating-non-muscle-invasive-bladder-cancer-a-population-health-and-payer-perspective 2025-12-23 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/prescription-digital-therapeutics-in-behavior-driven-conditions 2021-06-02 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/population-health-perspectives-examining-infertility 2024-10-17 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/exploring-novel-treatment-options-for-interstitial-pulmonary-fibrosis-and-progressive-pulmonary 2025-04-15 0.50 https://www.managedhealthcareexecutive.com/population-health-perspectives/challenges-and-opportunities-in-the-management-of-multi-drug-resistant-hiv 2022-12-19 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/efficacy-and-safety-of-intravenous-induction-and-subcutaneous-maintenance-therapy-with 2025-09-30 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/long-term-outcomes-with-lorlatinib-vs-crizotinib-in-alk-positive-nsclc-insights-from-the-7-year 2026-06-10 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/exploring-real-world-atopic-dermatitis-treatment-patterns 2025-03-17 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/beyond-the-primary-endpoint-diving-deeper-into-the-emerald-trial 2025-10-10 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/bimekizumab-and-patient-reported-outcomes-and-work-productivity-in-patients-with-psoriatic 2025-09-08 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/longer-term-treatment-with-nusinersen-results-in-later-onset-spinal-muscular-atrophy-from-the 2023-12-21 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/immunotherapy-in-advanced-non-small-cell-lung-cancer-5-year-outcomes-from-empower-lung-3 2026-03-30 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/data-driven-diabetes-continuous-glucose-monitoring-updates-and-economic-impacts 2026-04-06 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/sarilumab-for-relapse-of-polymyalgia-rheumatica-during-glucocorticoid-taper-saphyr-trial 2023-12-06 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/ruxolitinib-for-polycythemia-vera-intolerant-or-resistant-to-hydroxyurea 2024-05-02 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/results-and-implications-from-the-open-label-arm-of-the-true-v-long-term-extension-phase-3-study 2023-10-20 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/healthcare-resource-utilization-in-patients-with-type-1-diabetes-with-or-without-prior-type-2 2025-06-24 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/cemiplimab-monotherapy-and-5-year-outcomes-in-advanced-non-small-cell-lung-cancer-results-and 2025-03-24 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/between-the-lines-a-head-to-head-phase-3b-comparison-of-bimekizumab-versus-risankizumab-in 2026-08-14 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/fsgs-in-focus-interpreting-duplex-trial-data-for-clinical-practice-and-payer-policy 2026-07-29 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/bempedoic-acid-and-cardiovascular-outcomes-in-statin-intolerant-patients 2025-05-29 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/clinical-trial-updates-on-treatments-targeting-braf-v600e-in-metastatic-non-small-cell-lung 2025-12-22 0.50 https://www.managedhealthcareexecutive.com/between-the-lines/cost-effectiveness-analysis-of-rebyota-tm-fecal-microbiota-live-jslm-fmbl-versus-standard-of 2023-08-18 0.50 https://www.managedhealthcareexecutive.com/k-cast/type-1-diabetes-in-focus-optimizing-outcomes-with-early-intervention 2025-03-28 0.50 https://www.managedhealthcareexecutive.com/k-cast/exploring-recent-guideline-updates-relating-to-the-management-of-hyperlipidemia 2025-09-30 0.50 https://www.managedhealthcareexecutive.com/k-cast/elevating-atopic-dermatitis-care 2024-05-16 0.50 https://www.managedhealthcareexecutive.com/k-cast/prescription-digital-therapeutics-addressing-unmet-needs-among-patients-with-mental-health 2024-08-13 0.50 https://www.managedhealthcareexecutive.com/k-cast/optimizing-narcolepsy-care-diagnosis-treatment-and-patient-access 2025-02-03 0.50 https://www.managedhealthcareexecutive.com/k-cast/insights-into-digital-therapeutics-space-and-associated-evidence-thresholds 2024-03-28 0.50 https://www.managedhealthcareexecutive.com/k-cast/enhancing-patient-care-in-ppf-strategies-for-addressing-unmet-needs-and-optimizing-treatment 2024-12-17 0.50 https://www.managedhealthcareexecutive.com/k-cast/optimizing-biosimilar-implementation-a-framework-for-access-adoption-and-sustainability 2025-01-30 0.50 https://www.managedhealthcareexecutive.com/k-cast/paradigms-in-insulin-use-for-type-2-diabetes 2021-12-22 0.50 https://www.managedhealthcareexecutive.com/k-cast/advances-in-the-treatment-of-demodex-blepharitis 2024-05-02 0.50 https://www.managedhealthcareexecutive.com/k-cast/redefining-readiness-are-we-prepared-for-the-bispecific-era-in-multiple-myeloma 2025-07-24 0.50 https://www.managedhealthcareexecutive.com/k-cast/management-of-dry-eye-disease 2022-06-07 0.50 https://www.managedhealthcareexecutive.com/k-cast/driving-diabetes-care-excellence-through-quality-measures 2024-08-08 0.50 https://www.managedhealthcareexecutive.com/k-cast/updates-in-vaccine-management-from-a-population-health-lens 2023-04-21 0.50 https://www.managedhealthcareexecutive.com/k-cast/innovations-in-reproductive-medicine-implications-for-health-benefit-design 2023-11-30 0.50 https://www.managedhealthcareexecutive.com/k-cast/a-clinician-s-perspective-on-emerging-therapies-and-managed-care-challenges-in-vitiligo 2024-11-11 0.50 https://www.managedhealthcareexecutive.com/k-cast/value-based-decision-making-in-metastatic-breast-cancer 2021-06-15 0.50 https://www.managedhealthcareexecutive.com/k-cast/evaluating-chronic-kidney-disease-as-a-risk-factor-for-cardiovascular-disease 2025-09-30 0.50 https://www.managedhealthcareexecutive.com/k-cast/examining-evolving-treatment-paradigms-in-the-hemophilia-b-space 2022-08-11 0.50 https://www.managedhealthcareexecutive.com/k-cast/overcoming-challenges-in-diagnosis-and-management-of-demodex-blepharitis 2023-10-06 0.50 https://www.managedhealthcareexecutive.com/k-cast/optimizing-myelofibrosis-management-clinical-strategies-treatment-innovations-and-financial 2024-07-24 0.50 https://www.managedhealthcareexecutive.com/k-cast/updates-in-the-treatment-of-vitiligo 2022-09-02 0.50 https://www.managedhealthcareexecutive.com/k-cast/improving-access-to-appropriate-therapies-in-atopic-dermatitis 2022-05-09 0.50 https://www.managedhealthcareexecutive.com/k-cast/considerations-for-biosimilars-unbranded-biologics-and-originator-biologics 2023-08-29 0.50 https://www.managedhealthcareexecutive.com/k-cast/exploring-key-unmet-needs-in-idiopathic-pulmonary-fibrosis 2024-08-01 0.50 https://www.managedhealthcareexecutive.com/k-cast/no-transplant-no-problem-redefining-first-line-myeloma-care-with-anti-cd38-therapies 2025-06-27 0.50 https://www.managedhealthcareexecutive.com/k-cast/unbranded-biologics-an-overview 2022-08-10 0.50 https://www.managedhealthcareexecutive.com/k-cast/evolving-scac-care-clinical-perspectives-on-innovation-and-implementation 2025-06-27 0.50 https://www.managedhealthcareexecutive.com/k-cast/comprehensive-insight-into-atopic-dermatitis-understanding-disease-burden-treatment-strategies 2025-05-22 0.50 https://www.managedhealthcareexecutive.com/k-cast/the-bispecific-era-in-multiple-myeloma-future-directions 2026-04-20 0.50 https://www.managedhealthcareexecutive.com/k-cast/key-patient-considerations-for-the-utilization-of-intravenous-and-subcutaneous-therapies 2024-08-26 0.50 https://www.managedhealthcareexecutive.com/k-cast/advancing-healthcare-with-prescription-digital-therapeutics 2024-04-16 0.50 https://www.managedhealthcareexecutive.com/k-cast/evolving-treatment-paradigms-in-hemophilia 2025-10-27 0.50 https://www.managedhealthcareexecutive.com/k-cast/updates-in-the-management-of-demodex-blepharitis 2022-10-31 0.50 https://www.managedhealthcareexecutive.com/k-cast/highlighting-rare-disease-spinal-muscular-atrophy-sma-management-considerations 2022-11-04 0.50 https://www.managedhealthcareexecutive.com/k-cast/current-and-emerging-treatment-strategies-in-follicular-lymphoma 2026-09-09 0.50 https://www.managedhealthcareexecutive.com/k-cast/supporting-better-cancer-care-through-comprehensive-genomic-profiling-cgp- 2021-12-08 0.50 https://www.managedhealthcareexecutive.com/k-cast/advances-in-biomarker-driven-therapy-for-advanced-nsclc 2021-06-08 0.50 https://www.managedhealthcareexecutive.com/k-cast/overview-of-spinal-muscular-atrophy 2023-03-15 0.50 https://www.managedhealthcareexecutive.com/k-cast/challenges-and-considerations-in-treatment-of-adult-spinal-muscular-atrophy 2021-06-08 0.50 https://www.managedhealthcareexecutive.com/podcasts/conversations-with-perry 2026-08-28 0.50 https://www.managedhealthcareexecutive.com/videos 2020-04-22 0.50